Allergic contact dermatitis to personal care products and topical medications in adults with atopic dermatitis - 10/11/18
Abstract |
Background |
Atopic dermatitis (AD) is associated with skin-barrier disruption, immune dysregulation, and application of emollients and topical medications that might predispose a person toward developing allergic contact dermatitis.
Objective |
To determine the predictors of allergic contact dermatitis and relevant allergens in AD.
Methods |
A retrospective chart review was performed for 502 adults (age ≥18 years) who were patch tested to an expanded allergen series during 2014-2017.
Results |
Overall, 108 (21.5%) had current AD and 109 (21.7%) had past AD. Patients with and without current AD had similar proportions of any positive (+, ++, or +++ 80 [74.1%] vs 254 [64.5%], respectively, chi-squared P = .06); strong-positive (++ and +++ 34 [31.5%] vs 102 [25.9%], respectively, P = .25); and irritant (56 [51.9%] vs 188 [47.7%], respectively, P = .45) patch-test reactions. AD patients had significantly higher rates of positive reactions to ingredients in their personal care products and topical medications, including fragrance mix II (P = .04), lanolin (P = .03), bacitracin (P = .04), cinnamal (P = .02), budesonide (P = .01), tixocortol (P = .02), and chlorhexidine (P = .001); relevance was established in >90% of these reactions. Polysensitization occurred more commonly in patients with AD than without (35 [32.4%] vs 75 [19.0%]; P = .01).
Limitation |
Study was performed at a single center.
Conclusion |
AD patients had more positive patch-test reactions to ingredients in their personal care products, topical steroids, and antibiotics.
Le texte complet de cet article est disponible en PDF.Key words : allergic contact dermatitis, atopic dermatitis, eczema, polysensitization
Abbreviations used : ACD, AD, aOR, CI, NACDG, PPTR, SD
Plan
| Funding sources: Supported by the Dermatology Foundation. REDCap is supported at the Feinberg School of Medicine by the Northwestern University Clinical and Translational Science Institute. Research reported in this publication was supported, in part, by the National Institutes of Health's National Center for Advancing Translational Sciences, Grant Number UL1TR001422. |
|
| Conflicts of interest: None disclosed. |
|
| Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
|
| Previously presented: Presented in part at the 10th Georg Rajka International Symposium on Atopic Dermatitis in Utrecht, The Netherlands, on April 11-13, 2018. |
Vol 79 - N° 6
P. 1028 - décembre 2018 Retour au numéro
Article précédent
- Bullae for you: The increasing importance and implications of drug-induced bullous pemphigoid
- Warren R. Heymann
- Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study
- Outi Varpuluoma, Anna-Kaisa Försti, Jari Jokelainen, Miia Turpeinen, Markku Timonen, Kaisa Tasanen, Laura Huilaja
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?